Harbor Capital Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Harbor Capital Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.64M	Sell	30,353 -10,543	-26%	-$1.03M	0.21%	127
2025 Q4	$4.38M	Buy	40,896 +3,691	+10%	+$392K	0.34%	51
2025 Q3	$3.76M	Sell	37,205 -49,341	-57%	-$4.58M	0.29%	69
2025 Q2	$5.47M	Buy	86,546 +9,249	+12%	+$566K	0.23%	145
2025 Q1	$4.09M	Buy	77,297 +47,045	+156%	+$2.61M	0.19%	175
2024 Q4	$1.69M	Sell	30,252 -11,116	-27%	-$614K	0.07%	340
2024 Q3	$2.17M	Buy	41,368 +6,741	+19%	+$323K	0.09%	288
2024 Q2	$1.42M	Buy	34,627 +11,846	+52%	+$473K	0.11%	272
2024 Q1	$987K	Buy	+22,781	New	+$997K	0.13%	218

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Harbor Capital Advisors's RYTM Position: Q1 2026 in Review

Harbor Capital Advisors reduced its Rhythm Pharmaceuticals (RYTM) stake by 26% in Q1 2026, selling an estimated $1.03M and leaving 30,353 shares worth $2.64M. The position accounts for 0.21% of the portfolio, ranked #127.

Harbor Capital Advisors first reported a position in RYTM in Q1 2024 and has held it in 9 quarters since. The position peaked at $5.47M in Q2 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

Harbor Capital Advisors held 30,353 shares of Rhythm Pharmaceuticals worth $2.64M as of Q1 2026.
Harbor Capital Advisors sold 10,543 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $1.03M.
Rhythm Pharmaceuticals made up 0.21% of Harbor Capital Advisors's portfolio in Q1 2026, its #127 holding.
Harbor Capital Advisors first reported a position in Rhythm Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Harbor Capital Advisors's Rhythm Pharmaceuticals position peaked at $5.47M in Q2 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.